Karolinska Development’s portfolio company Umecrine Cognition publishes data on the benefits of early treatment with golexanolone in Parkinson’s disease

Core Insights - Umecrine Cognition has published data indicating that early treatment with golexanolone may delay the progression of Parkinson's disease symptoms and postpone the need for L-DOPA treatment [1][4] Company Overview - Karolinska Development AB holds a 60 percent ownership stake in Umecrine Cognition, which is focused on developing a new class of drugs to alleviate cognitive symptoms associated with Parkinson's disease [4] - The company is a Nordic life sciences investment firm that identifies and invests in breakthrough medical innovations in the Nordic region [5][6] Research Findings - A preclinical study shows that early administration of golexanolone leads to stronger and longer-lasting relief from symptoms compared to later treatment [3] - The study demonstrated significant reductions in severe fatigue and lack of movement, along with enhanced motor coordination and improved gross motor function [3][4] - Golexanolone appears to rebalance key neurotransmitter systems in the brain, suggesting its potential as a disease-modifying treatment rather than merely providing symptomatic relief [4]